A61K 39/39583
Against materials not provided for elsewhere
Official title: {against materials not provided for elsewhere, e.g. haptens, coenzymes}
A61K39/39583 (Against materials not provided for elsewhere) appears on 71 US grants and 138 published applications in this corpus.
Search patents in A61K- Granted patents
- 71
- Published applications
- 138
- Assignees
- 64
- Inventors
- 216
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 0 | 1 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 2 |
| 2007 | 0 | 3 |
| 2008 | 0 | 5 |
| 2009 | 1 | 1 |
| 2010 | 1 | 5 |
| 2011 | 1 | 6 |
| 2012 | 1 | 4 |
| 2013 | 5 | 7 |
| 2014 | 8 | 11 |
| 2015 | 5 | 12 |
| 2016 | 10 | 17 |
| 2017 | 5 | 11 |
| 2018 | 3 | 7 |
| 2019 | 5 | 5 |
| 2020 | 5 | 6 |
| 2021 | 6 | 10 |
| 2022 | 2 | 8 |
| 2023 | 3 | 4 |
| 2024 | 2 | 3 |
| 2025 | 5 | 6 |
| 2026 | 3 | 4 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Enhancement of immune response with oral immunoglobulin polypeptides6 Oct 2026US 12,752,004 B2Iogenetics, LLC
- Methods of reversing ticagrelor activity5 May 2026US 12,617,870 B2SFJ Pharmaceutical X, LTD.
- Cytotoxicity targeting chimeras for CCR2-expressing cells13 Jan 2026US 12,521,393 B2GlaxoSmithKline Intellectual Property Development Limited
- Chemically controlled monoclonal antibody target engagement2 Dec 2025US 12,486,334 B2The Regents of the University of California
- Methods for identifying beta-glucan binding to immune cells19 Aug 2025US 12,390,526 B2HiberCell, Inc.
- Methods of reversing ticagrelor activity23 Jul 2026US 2026/0209389 A1SFJ Pharmaceuticals X, Ltd.
- Chemically controlled monoclonal antibody target engagement23 Apr 2026US 2026/0109786 A1The Regents of the University of California
- Treatment method26 Feb 2026US 2026/0053917 A1Hoffmann-La Roche Inc.
- Cytotoxicity targeting chimeras for ccr2-expressing cells12 Feb 2026US 2026/0041686 A1GlaxoSmithKline Intellectual Property Development Limited
- System and method for the development of cd30 bispecific antibodies for immunotherapy of cd30+ malignancies13 Nov 2025US 2025/0346680 A1The Medical College of Wisconsin, Inc.
Most cited
By later US patents
- Anticoagulant antidotes comprising antibodies that bind dabigatran and/or related compounds18US 8,486,398 B2Boehringer Ingelheim International GmbH · 2013
- Treatment of food intolerance and food allergy with IgM18US 9,273,129 B22016
- Method of treating a pathological syndrome and a pharmaceutical agent16US 7,815,904 B22010
- Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments15US 8,333,971 B2Immunomedics, Inc. · 2012
- Method of treating a pathological syndrome and a pharmaceutical agent14US 8,535,664 B22013